Drugs (nursing considerations)

Question 1

Romidepsin (Istodax)

Answer 1

“Vital Signs: Assess prior to infusion and periodically during and after infusion.
Additional information:Monitor INR more frequently in patients on Warfarin. Monitor with baseline EKG and assess for EKG changes periodically during treatment. Assess for reactivation of Hep B or Epstein Barr. Tumor Lysis Syndrome in advanced stage disease or high tumor burden at greater risk.
Avoid co-administration of ISTODAX with rifampin or concomitant use of CYP3A4 inhibitors/grapefruit juice. “

Question 2

Rituximab-pvvr (Ruxience)

Answer 2

“Vital Signs:Assess Vitals Signs every 30 minutes or with rate change.
Additional Information: Tumor lysis syndrome prevention: Administer aggressive intravenous hydration,anti-hyperuricemic agents, monitor renal function. Infections: Withhold Rituxan and institute appropriate anti-infective therapy. Cardiac arrhythmias and angina: Discontinue. Do not administer live virus vaccines prior to or during Rituxan .”

Question 3

ABATACEPT

Answer 3

“Vital Signs: None required
Lab Value Assessment: Patient will have falsely elevated glucose on day of infusion. “

Question 4

FILGRASTIM-SNDZ

Answer 4

Lab Value Assessment: CBC/Diff, platelet count, LDH, ALK Phos

Question 5

“ADO-TRASTUZUMAB EMTANSINE (KADCYLA)
“

Answer 5

“Vital Signs: Prior to and after Administration
Lab Value Assessment: CBC, K and LFT’s prior to each cycle.
Additional Information: Baseline LVEF. Patient must wait 90min after 1st dose and 30 minutes after subsequent doses. “

Question 6

ROMIPLOSTIM (NPlate)

Answer 6

Increased risk of bleeding. Targeted therapy TPO receptor. Too much roimiplostim may incrase the risk for blood clots.”

Question 7

4. ETOPOSIDE (toposar; VP-16)

Answer 7

“Vital Signs: Assessment prior to treatment Risk of Hypotension if given as fast bolus (give over 30-60 minutes to avoid)”

Question 8

8. AZACITIDINE (VIDAZA)

Answer 8

“Vital Signs: Not required
Avoid measures that may induce bleeding, such as taking a rectal temperature, enemas, suppositories or any other IM injections.New injection sites should be 1”” from previous injection sites.Hazardous drug”

Question 9

LEUCOVORIN CALCIUM (Wellcovorin)

Answer 9

Yes

Question 10

IRINOTECAN LIPOSOME (Onivyde)

Answer 10

“Vital Signs: Assessment prior to all treatment’s and after with first infusion

Question 11

SACITUZUMAB GOVITECAN-hziy (Trodelvy)

Answer 11

Monitor for at least 30 minutes after infusion for reaction. Premedicate with antipyretics, H1 and H2 blocker, and corticosteriods, 5-HT3 receptor antagonist or a NK1 receptor antagonish. May consider Atropine administration for early diarrhea, if latent diarrhea evaluate for infectious causes and if ruled out then administer loperamide. Light sensitivity-protect bag from light. Do not breast feed while on treatment. “

Question 12

TRASTUZUMAB (Herceptin)

Answer 12

“Vital Signs: Assess prior to treatment
Additional Information: Needs Echo prior to start for EF measurement and or MUGA; not compatible with clindomycin, lasix, levofloxan, morphine, zofran. “

Question 13

SOMATULINE DEPOT (Lanreotide)